NCT06567769View on ClinicalTrials.gov

Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA)

PHASE1RecruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 21, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Sanfilippo Syndrome Type A
Interventions
DRUG

GC1130A

ICV injection

Trial Locations (5)

55455

RECRUITING

University of Minnesota, Minneapolis

94609

RECRUITING

UCSF Benioff Children's Hospital, Oakland

Unknown

RECRUITING

National Center for Child Health and Development, Setagaya City

RECRUITING

Ajou University Medical Center, Suwon

RECRUITING

Samsung Medical Center, Seoul

Sponsors

Lead Sponsor

GC Biopharma Corp
All Listed Sponsors
lead

GC Biopharma Corp

INDUSTRY

NCT06567769 - Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | Biotech Hunter | Biotech Hunter